PharmaEssentia Valuation
Is 261280558 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 261280558 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 261280558 ($17.4) is trading below our estimate of fair value ($41.64)
Significantly Below Fair Value: 261280558 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 261280558?
Key metric: As 261280558 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 261280558's PE Ratio? | |
|---|---|
| PE Ratio | 102.1x |
| Earnings | NT$1.85b |
| Market Cap | NT$188.41b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 20.3x |
| Enterprise Value/EBITDA | 143.9x |
| PEG Ratio | 1.1x |
Price to Earnings Ratio vs Peers
How does 261280558's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 64.6x | ||
ADMA ADMA Biologics | 75.7x | 30.5% | US$5.2b |
AGIO Agios Pharmaceuticals | 5x | -56.7% | US$3.4b |
TLX Telix Pharmaceuticals | 161.8x | 38.3% | AU$7.8b |
HALO Halozyme Therapeutics | 15.7x | 21.1% | US$6.1b |
261280558 PharmaEssentia | 102.1x | 92.0% | US$188.4b |
Price-To-Earnings vs Peers: 261280558 is expensive based on its Price-To-Earnings Ratio (102.1x) compared to the peer average (63.8x).
Price to Earnings Ratio vs Industry
How does 261280558's PE Ratio compare vs other companies in the European Biotechs Industry?
| 5 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 5 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 261280558 is expensive based on its Price-To-Earnings Ratio (102.1x) compared to the European Biotechs industry average (26.5x).
Price to Earnings Ratio vs Fair Ratio
What is 261280558's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 102.1x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 261280558's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.